Jing L. Marantz - 26 Oct 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
28 Oct 2026, 16:06:38 UTC
Prior SEC filing
15 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ James Basta, attorney-in-fact
Filing notes and source

Key filing fact

Jing L. Marantz filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 28 Oct 2026.

Key facts

  • This page summarizes Jing L. Marantz's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 28 Oct 2026, 16:06.

Change

  • Previous filing in this sequence was filed on 15 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001834528 Primary reporting owner

Marantz Jing L.

Relationship
EVP, Chief Medical Officer
Address
C/O INTELLIA THERAPEUTICS, INC., 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE
Signature
/s/ James Basta, attorney-in-fact
Signature date
28 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTLA transaction

Common Stock

Award

Transaction value
Shares
+199,822
Change %
Price
$0.000000*
Shares after
199,822
Date
26 Oct 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NTLA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+275,061
Change %
Price
$0.000000*
Shares after
275,061
Date
26 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
275,061
Exercise price
$11.26
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Footnote F2

This option was granted on October 26, 2026 with respect to shares of Common Stock, with 33% vesting on October 26, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .